Enalaprilat en es it fr


Enalaprilat Nombres de marca, Enalaprilat Analogos

Enalaprilat Marca los nombres de mezcla

  • Vaseretic (Enalapril Maleate + Hydrochlorothiazide)
  • Enalaprilat Formula quimica


    Enalaprilat RX enlace


    Enalaprilat FDA hoja

    Enalaprilat FDA

    Enalaprilat MSDS (hoja de seguridad de materiales)

    Enalaprilat Sintesis de referencia

    A. Patchett et al., Nature 288, 280 (1980)

    Enalaprilat Peso molecular

    376.447 g/mol

    Enalaprilat Punto de fusion


    Enalaprilat H2O Solubilidad


    Enalaprilat Estado


    Enalaprilat LogP


    Enalaprilat Formas de dosificacion

    Tableta, inyección IV

    Enalaprilat Indicacion

    Para el tratamiento de la hipertensión y la insuficiencia cardiaca. Se puede utilizar solo o en combinación con diuréticos tiazídicos.

    Enalaprilat Farmacologia

    Enalapril, una enzima convertidora de la angiotensina (ECA), es un profármaco que, cuando se hidroliza por estarases a su enalaprilato activo, se utiliza para tratar la hipertensión y la insuficiencia cardiaca, para reducir la proteinuria y la enfermedad renal en pacientes con nefropatías, y para evitar accidente cerebrovascular, infarto de miocardio y muerte cardíaca en pacientes de alto riesgo. Enalapril y enalaprilato inhibir la enzima convertidora de angiotensina (ACE) en seres humanos y animales. La ECA es una peptidil dipeptidasa que cataliza la conversión de angiotensina I en la sustancia vasoconstrictora de la angiotensina II. La angiotensina II también estimula la aldosterona la secreción de la corteza suprarrenal.

    Enalaprilat Absorcion


    Enalaprilat Toxicidad


    Enalaprilat Informacion de Pacientes

    Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

    Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician. Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACEinhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    Enalaprilat Organismos afectados

    Humanos y otros mamíferos